A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis

Journal of Experimental Therapeutics and Oncology

Volumn 10, Issue 2, 2012, Pages 155-162

  Auzenne, Edmond J ^a   Klostergaard, Jim ^a   Mandal, Pijus K ^b   Liao, Warren S ^b   Lu, Zhen ^b   Gao, Fengqin ^b   Bast, Robert C Jr ^b   Robertson, Fredika M ^b   McMurray, John S ^b  

^a Departments of Molecular and Cellular Oncology   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Phosphopeptide prodrug; SH2 domain; Signal transducer and activator of transcription 3; Stat3

Indexed keywords

CYCLIN D1; PEPTIDOMIMETIC AGENT; PEPTIDOMIMETIC PM 73G; PROTEIN SH2; STAT3 PROTEIN; SURVIVIN; TYROSINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG TARGETING; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; BIOMIMETICS; BREAST NEOPLASMS; FEMALE; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOPEPTIDES; PHOSPHORYLATION; PHOSPHOTYROSINE; PRODRUGS; SRC HOMOLOGY DOMAINS; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873388087     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Costantino L., and Barlocco D. (2008) STAT 3 as a Target for Cancer Drug Discovery, Curr. Med. Chem. 15: 834-843.
2. Darnell J. E. Jr. (2002) Transcription factors as targets for cancer therapy, Nat. Rev. Cancer 2: 740-749.
3. Yu H., and Jove R. (2004) The STATs of cancer-new molecular targets come of age, Nat. Rev. Cancer 4: 97-105.
4. Yue P. and Turkson J. (2009) Targeting STAT3 in cancer: How successful are we?, Expert Opin. Investig. Drugs 18: 45-56.
5. Akira S., Nishio Y., Inoue M., Wang X. J., Wei S., Matsusaka T., Yoshida K., Sudo T., Naruto M. and Kishimoto, T. (1994) Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway, Cell 77: 63-71.
6. Yang J. and Stark G. R. (2008) Roles of unphosphorylated STATs in signaling, Cell Res. 18: 443-451.
7. Wegrzyn J., Potla R., Chwae Y. J., Sepuri N. B., Zhang Q., Koeck T., Derecka M., Szczepanek K., Szelag M., Gornicka A., Moh A., Moghaddas S., Chen Q., Bobbili S., Cichy J., Dulak J., Baker D. P., Wolfman A., Stuehr D., Hassan M. O., Fu X. Y., Avadhani N., Drake J. I., Fawcett P., Lesnefsky E. J. and Larner, A. C. (2009) Function of mitochondrial Stat3 in cellular respiration, Science 323: 793-797.
8. Gough D. J., Corlett A., Schlessinger K., Wegrzyn J., Larner A. C. and Levy D. E. (2009) Mitochondrial STAT3 supports Ras-dependent oncogenic transformation, Science 324: 1713-1716.
9. Waksman G., Kumaran S. and Lubman, O. (2004) SH2 domains: Role, structure and implications for molecular medicine, Expert Reviews in Molecular Medicine 6: 1-18.
10. Sawyer T. K. (1998) Src homology-2 domains: Structure, mechanisms, and drug discovery, Biopolymers 47: 243-261.
11. Cody W. L., Lin Z., Panek R. L., Rose D. W. and Rubin J. R. (2000) Progress in the development of inhibitors of SH2 domains, Curr. Pharm. Des. 6: 59-98.
12. Muller G. (2001) Peptidomimetic SH2 domain antagonists for targeting signal transduction., Topics in Current Chemistry 211: 17-59.
13. Shakespeare W. C. (2001) SH2 domain inhibition: A problem solved?, Curr. Opin. Chem. Biol. 5: 409-415.
14. Metcalf C. A., III and Sawyer T. (2004) Src homology-2 domains and structure-based, small-molecule library approaches to drug discovery, in Drug Discovery Strategies and Methods (Makriyannis, A., and Biegel, D., Eds.), pp 23-59, Marcel Dekker, Inc., New York, NY.
15. Garcia-Echeverria C. (2001) Antagonists of the homology 2 (SH2) domains of Grb2, Src, Lck and ZAP-70, Curr. Med. Chem. 8: 1589-1604.
16. Garcia-Echeverria C. (2006) Inhibitors of signaling interfaces: Targeting Src homology 2 domains in drug discovery, Protein Tyrosine Kinases 31-52.
17. Fletcher S., Singh J., Zhang X., Yue P., Page B. D., Sharmeen S., Shahani V. M., Zhao W., Schimmer A. D., Turkson J. and Gunning, P. T. (2009) Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: Potent in vitro and tumor cell activities, Chembiochem 10: 1959-1964.
18. Gunning P. T., Katt W. P., Glenn M., Siddiquee K., Kim J. S., Jove R., Sebti S. M., Turkson J. and Hamilton A. D. (2007) Isoform selective inhibition of STAT1 or STAT3 homodimerization via peptidomimetic probes: Structural recognition of STAT SH2 domains, Bioorg. Med. Chem. Lett. 17: 1875-1878.
19. Shahani V. M., Yue P., Fletcher S., Sharmeen S., Sukhai M. A., Luu D. P., Zhang X., Sun H., Zhao W., Schimmer A. D., Turkson J. and Gunning P. T. (2011) Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein, Bioorg. Med. Chem. 19: 1823-1838.
20. Shahani V. M., Yue P., Haftchenary S., Zhao W., Lukkarila J. L., Zhang X., Ball D., Nona C., Gunning P. T. and Turkson J. (2011) Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies, ACS Med. Chem. Lett. 2: 79-84.
21. Siddiquee K. A., Gunning P. T., Glenn M., Katt W. P., Zhang S., Schrock C., Sebti S. M., Jove R., Hamilton A. D. and Turkson J. (2007) An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects, ACS Chem. Biol. 2: 787-798.
22. Turkson J., Kim J. S., Zhang S., Yuan J., Huang M., Glenn M., Haura E., Sebti S., Hamilton A. D. and Jove R. (2004) Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity, Mol. Cancer. Ther. 3: 261-269.
23. Turkson J., Ryan D., Kim J. S., Zhang Y., Chen Z., Haura E., Laudano A., Sebti S., Hamilton A. D. and Jove R. (2001) Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation, The Journal of biological chemistry 276: 45443-45455.
24. Zhang X., Yue P., Fletcher S., Zhao W., Gunning P. T. and Turkson J. (2010) A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes, Biochem. Pharmacol. 79: 1398-1409.
25. Shao H., Cheng H. Y., Cook R. G. and Tweardy D. J. (2003) Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor, Cancer research 63: 3923-3930.
26. Shao H., Xu X., Mastrangelo M. A., Jing N., Cook R. G., Legge G. B. and Tweardy D. J. (2004) Structural requirements for signal transducer and activator of transcription 3 binding to phosphotyrosine ligands containing the YXXQ motif, The Journal of biological chemistry 279: 18967-18973.
27. Xu X., Kasembeli M. M., Jiang X., Tweardy B. J. and Tweardy D. J. (2009) Chemical probes that competitively and selectively inhibit Stat3 activation, PloS one 4: E4783.
28. Chen J., Bai L., Bernard D., Nikolovska-Coleska Z., Gomez C., Zhang J., Yi H. and Wang S. (2010) Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors, ACS Med. Chem. Lett. 1: 85-89.
29. Chen J., Nikolovska-Coleska Z., Yang C. Y., Gomez C., Gao W., Krajewski K., Jiang S., Roller P. and Wang S. (2007) Design and synthesis of a new, conformationally constrained, macrocyclic small-molecule inhibitor of STAT3 via 'click chemistry', Bioorg. Med. Chem. Lett. 17: 3939-3942.
30. Dourlat J., Valentin B., Liu W. Q. and Garbay C. (2007) New syntheses of tetrazolylmethylphenylalanine and O-malonyltyrosine as pTyr mimetics for the design of STAT3 dimerization inhibitors, Bioorg. Med. Chem. Lett. 17: 3943-3946.
31. Stahl N., Farruggella T. J., Boulton T. G., Zhong Z., Darnell J. E., Jr. and Yancopoulos G. D. (1995) Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors, Science 267: 1349-1353.
32. Gerhartz C., Heesel B., Sasse J., Hemmann U., Landgraf C., Schneider-Mergener J., Horn F., Heinrich P. C. and Graeve L. (1996) Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation, The Journal of biological chemistry 271: 12991-12998.
33. Coleman D. R. I., Kaluarachchi K., Ren Z., Chen X. and McMurray J. S. (2008) Solid phase synthesis of phosphopeptides incorporating 2,2-dimethyloxazolidine pseudoproline analogs: Evidence for trans Leu-Pro peptide bonds in Stat3 inhibitors, Int. J. Pept. Res. Ther. 14: 1-9.
34. Coleman D. R. I., Ren Z., Mandal P. K., Cameron A. G., Dyer G. A., Muranjan S., Campbell M., Chen X. and McMurray J. S. (2005) Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor, J. Med. Chem. 48: 6661-6670.
35. Mandal P. K., Heard P. A., Ren Z., Chen X. and McMurray J. S. (2007) Solid-phase synthesis of Stat3 inhibitors incorporating O-carbamoylserine and O-carbamoylthreonine as glutamine mimics, Bioorg. Med. Chem. Lett. 17: 654-656.
36. Mandal P. K., Ren Z., Chen X., Xiong C. and McMurray J. S. (2009) Structure-affinity relationships of glutamine mimics incorporated into phosphopeptides targeted to the SH2 domain of signal transducer and activator of transcription 3, J. Med. Chem. 52: 6126-6141.
37. Ren Z., Cabell L. A., Schaefer T. S. and McMurray J. S. (2003) Identification of a high-affinity phosphopeptide inhibitor of Stat3, Bioorg. Med. Chem. Lett. 13: 633-636.
38. Mandal P. K., Limbrick D., Coleman D. R., Dyer G. A., Ren Z., Birtwistle J. S., Xiong C., Chen X., Briggs J. M. and McMurray J. S. (2009) Conformationally constrained peptidomimetic inhibitors of signal transducer and activator of transcription 3: Evaluation and molecular modeling, J. Med. Chem. 52: 2429-2442.
39. McMurray J. S. (2008) Structural basis for the binding of high affinity phosphopeptides to Stat3, Biopolymers 90: 69-79.
40. Dhanik A., McMurray J. S. and Kavraki L. (2012) On modeling peptidomimetics in complex with the SH2 domain of Stat3, Conf Proc IEEE Eng Med Biol Soc 2011: 3229-3232.
41. Mandal P. K., Gao F., Lu Z., Ren Z., Ramesh R., Birtwistle J. S., Kaluarachchi K. K., Chen X., Bast R. C., Liao W. S. and McMurray J. S. (2011) Potent and Selective Phosphopeptide Mimetic Prodrugs Targeted to the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3, J. Med. Chem. 54: 3549-5463.
42. Mandal P. K., Liao W. S. and McMurray J. S. (2009) Synthesis of phosphatase-stable, cell-permeable peptidomimetic prodrugs that target the SH2 domain of Stat3, Org. Lett. 11: 3394-3397.
43. Chen Z. and Han Z. C. (2008) STAT3: A critical transcription activator in angiogenesis, Med. Res. Rev. 28: 185-200.
44. Atabey N., Gao Y., Yao Z. J., Breckenridge D., Soon L., Soriano J. V., Burke T. R., Jr. and Bottaro D. P. (2001) Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions, The Journal of biological chemistry 276: 14308-14314.
45. Giubellino A., Gao Y., Lee S., Lee M. J., Vasselli J. R., Medepalli S., Trepel J. B., Burke T. R., Jr. and Bottaro D. P. (2007) Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist, Cancer research 67: 6012-6016.
46. Soriano J. V., Liu N., Gao Y., Yao Z. J., Ishibashi T., Underhill C., Burke T. R., Jr. and Bottaro D. P. (2004) Inhibition of angiogenesis by growth factor receptor bound protein 2-Src homology 2 domain bound antagonists, Mol. Cancer Ther. 3: 1289-1299.
47. Garrido-Hernandez H., Moon K. D., Geahlen R. L. and Borch R. F. (2006) Design and synthesis of phosphotyrosine peptidomimetic prodrugs, J. Med. Chem. 49: 3368-3376.
48. Gay B., Suarez S., Weber C., Rahuel J., Fabbro D., Furet P., Caravatti G. and Schoepfer, J. (1999) Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility, The Journal of biological chemistry 274: 23311-23315.
49. Gay B., Suarez S., Caravatti G., Furet P., Meyer T. and Schoepfer J. (1999) Selective GRB2 SH2 inhibitors as anti-Ras therapy, Int. J. Cancer 83: 235-241.
50. Liu W. Q., Vidal M., Mathe C., Perigaud C. and Garbay C. (2000) Inhibition of the ras-dependent mitogenic pathway by phosphopeptide prodrugs with antiproliferative properties, Bioorg. Med. Chem. Lett. 10: 669-672.
51. Liu W. Q., Vidal M., Olszowy C., Million E., Lenoir C., Dhotel H. and Garbay C. (2004) Structure-activity relationships of small phosphopeptides, inhibitors of Grb2 SH2 domain, and their prodrugs, J. Med. Chem. 47: 1223-1233.
52. Stankovic C. J., Surendran N., Lunney E. A., Plummer M. S., Para K. S., Shahripour A., Fergus J. H., Marks J. S., Herrera R., Hubbell S. E., Humblet C., Saltiel A. R., Stewart B. H. and Sawyer T. K. (1997) The role of 4-phosphonodifluoromethyland 4-phosphono-phenylalanine in the selectivity and cellular uptake of SH2 domain ligands, Bioorg. Med. Chem. Lett. 7: 1909-1914.
53. Bromberg J. and Darnell J. E., Jr. (2000) The role of STATs in transcriptional control and their impact on cellular function, Oncogene 19: 2468-2473.
54. Levy D. E. and Darnell J. E., Jr. (2002) Stats: Transcriptional control and biological impact, Nat. Rev. Mol. Cell. Biol. 3: 651-662.
55. Kreis S., Munz G. A., Haan S., Heinrich P. C. and Behrmann I. (2007) Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases, Mol. Cancer Res. 5: 1331-1341.
56. Hedvat M., Huszar D., Herrmann A., Gozgit J. M., Schroeder A., Sheehy A., Buettner R., Proia D., Kowolik C. M., Xin H., Armstrong B., Bebernitz G., Weng S., Wang L., Ye M., McEachern K., Chen H., Morosini D., Bell K., Alimzhanov M., Ioannidis S., McCoon P., Cao Z. A., Yu H., Jove R. and Zinda M. (2009) The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors, Cancer Cell 16: 487-497.
57. Xin H., Herrmann A., Reckamp K., Zhang W., Pal S., Hedvat M., Zhang C., Liang W., Scuto A., Weng S., Morosini D., Cao Z. A., Zinda M., Figlin R., Huszar D., Jove R. and Yu H. (2011) Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480, Cancer Res. 71: 6601-6610.
58. Looyenga B. D., Hutchings D., Cherni I., Kingsley C., Weiss G. J. and Mackeigan J. P. (2012) STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma, PLoS One 7: E30820.
59. Niu G., Wright K. L., Huang M., Song L., Haura E., Turkson J., Zhang S., Wang T., Sinibaldi D., Coppola D., Heller R., Ellis L. M., Karras J., Bromberg J., Pardoll D., Jove R. and Yu H. (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis, Oncogene 21: 2000-2008.
60. Gray M. J., Zhang J., Ellis L. M., Semenza G. L., Evans D. B., Watowich S. S. and Gallick G. E. (2005) HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas, Oncogene 24: 3110-3120.